04:59 AM EDT, 07/14/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Sunday that new data evaluating its once-daily, oral investigational drug Palsonify in acromegaly showed insulin-like growth factor 1 levels remaining stable, with durable biochemical control over 96 weeks.

Growth hormone levels were also stable at 96 weeks in the phase 3 study.

In another 114-patient phase 3 study, patients receiving the drug showed "durably controlled" symptom scores and pituitary tumor sizes compared with those receiving placebo, the company said.

Palsonify was generally "well tolerated" in both studies, Crinetics said.

Acromegaly is a rare disease caused by the overproduction of growth hormone, often because of a benign tumor on the pituitary gland, and leading to enlargement of bones and tissues.